Topic

Aetna (CVS Health)

A collection of 1074 issues

How to Get Nourianz (Istradefylline) Approved by Aetna CVS Health in Pennsylvania: Step-by-Step Prior Authorization Guide

Answer Box: Getting Nourianz (Istradefylline) Approved by Aetna CVS Health in Pennsylvania Aetna CVS Health requires prior authorization for Nourianz (istradefylline) with step therapy requirements in Pennsylvania. You'll need documented failure of amantadine, MAO-B inhibitors (like rasagiline), or COMT inhibitors (like entacapone), plus proof of 3+ hours daily
6 min read

How to Get Rinvoq (upadacitinib) Covered by Aetna (CVS Health) in Virginia: Complete Guide with Forms, Timelines, and Appeal Scripts

Answer Box: Fastest Path to Rinvoq (upadacitinib) Coverage Aetna (CVS Health) requires prior authorization for Rinvoq (upadacitinib) in Virginia, mandating documented failure or intolerance to at least one TNF inhibitor. Submit your PA request via Aetna's provider portal or CoverMyMeds with complete clinical documentation including prior therapy records,
7 min read

Renewing Naglazyme (Galsulfase) Approval with Aetna (CVS Health) in Michigan: 2025 Timeline and Documentation Guide

Quick Answer: Renewing Your Naglazyme Coverage Start renewal 60-90 days before expiration. Contact your metabolic specialist to update functional assessments (6-minute walk test, stair climbing capacity) and prepare a medical necessity letter documenting continued clinical benefit. Submit through CVS Specialty Pharmacy or CoverMyMeds portal. If denied, you have 180 days
5 min read

Aetna's Coverage Criteria for Hemlibra (emicizumab-kxwh) in Michigan: What Counts as "Medically Necessary"?

Answer Box: Getting Hemlibra Covered by Aetna in Michigan Aetna requires prior authorization for Hemlibra (emicizumab-kxwh) with medical necessity established through confirmed hemophilia A diagnosis, routine prophylaxis indication, and hematologist prescription. Michigan patients have strong appeal rights through DIFS external review within 127 days of denial. First step today: Contact
6 min read